Oppenheimer Upgrades Genoptix (GXDX) to Outperform
Oppenheimer upgrades Genoptix (Nasdaq: GXDX) from Perform to Outperform. Price target increased from $33 to $44.
To see more analyst ratings on GXDX Click Here.
Genoptix, Inc. (Genoptix) is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists (hema/oncs).
Related Categories
UpgradesStocks Mentioned
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
